Vasopressin Market to Surpass US$ 2,912.0 Million by 2028

Global Vasopressin Market, by Type (Intravenous Injection, Intramuscular Injection, and Subcutaneous Injection), by Application, (Anti-Diuretic Hormone Deficiency, Gastrointestinal Bleeding, Vasodilatory Shock and Ventricular Tachycardia & Fibrillation), by End User (Hospitals, Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,112.6  million in 2021 and is expected to exhibit a CAGR of 14.7% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

The increasing approvals of vasopressin drug by regulatory authorities such as the U.S. Food and Drug Administration is expected to drive growth of the global vasopressin market over the forecast period.

For instance, in 2014, Par Pharmaceutical Companies, Inc.  received new drug application (NDA) approval for its Vasostrict from the U.S. Food and Drug Administration (FDA) pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act.

Vasostrict is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines.

Global Vasopressin Market– Impact of Coronavirus (COVID-19) Pandemic (economic Impact)

The coronavirus (COVID-19) pandemic and lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Private healthcare sector is one of the sectors, which is majorly impacted by the COVID 19 pandemic.

Coronavirus pandemic has negatively impacted the development, production, and supply of medicines and also affected growth of the pharmaceutical businesses of various companies across the globe, as COVID-19 pandemic has led to lockdown in several countries, globally. This lockdown has resulted in closure of industrial establishments, except manufacturing of essential commodities and disruption in supply chain of the pharmaceuticals and kits for diagnostic and therapeutic use.

Thus, COVID-19 pandemic has affected the economy in three main ways; 1) By directly affecting the production and demand; 2) By creating disruptions in distribution channels; and 3) By its financial impact on firms and financial markets.

Supply chain and manufacturing activities in India, China, and the U.S. are disrupted due to global lockdown, while many countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of pharmaceutical drugs from one place to another.

Browse 35 Market Data Tables and 32 Figures spread through 189 Pages and in-depth TOC on “Vasopressin Market”- Global Forecast to 2028, by Type (Intravenous Injection, Intramuscular Injection, and Subcutaneous Injection), by Application, (Anti-Diuretic Hormone Deficiency, Gastrointestinal Bleeding, Vasodilatory Shock and Ventricular Tachycardia & Fibrillation), by End User (Hospitals, Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the Global Vasopressin Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/vasopressin-market-4646

Key Takeaways of the Global Vasopressin Market:

• The global vasopressin market is expected to exhibit a CAGR of 14.7% over the forecast period, owing to increasing launches of vasopressin injection. For instance, in 2018, Athenex, Inc., a biopharmaceutical company launched compounded vasopressin injection in ready-to-use premix IV bags through its subsidiary Athenex Pharma Solutions (APS).
• Among application, gastrointestinal bleeding segment is estimated to account for the largest market share in 2021. The growth of the segment is attributed to increasing prevalence of gastrointestinal bleeding. For instance, according to the data published in Mayoclinic proceedings in 2019, around 350,000 patient are administered in hospital due to the upper gastrointestinal bleeding in the U.S., annually.
• Key players operating in the global vasopressin market include Par Pharmaceutical, Pfizer Inc., Novartis AG, Ferring Pharmaceuticals, Fresenius Kabi Canada, Astellas Pharma, Shanghai Soho-Yiming Pharmaceuticals, Endo International, Hybio Pharmaceutical, Hainan Zhonghe Pharmaceutical, and Cumberland Pharmaceuticals